Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The sialic acid analogue zanamivir (GG167) is a selective inhibitor of influenza A and B virus neuraminidases. These viral enzymes are essential for the release of virus from infected cells, and they may also reduce the inactivation of virus by respiratory secretions. When administered experimentally directly to the respiratory tract, zanamivir has potent antiviral effects. We assessed the therapeutic activity of zanamivir in adults with acute influenza.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N Engl J Med

Title: The New England journal of medicine

Publisher: Massachusetts Medical Society

ISSN: 0028-4793

ISSN (Print): 0028-4793

Publication date (Electronic): Sep 25 1997

Volume: 337

Issue: 13

Affiliations

[1 ] University of Virginia, Charlottesville 22908, USA.

Article

DOI: 10.1056/NEJM199709253371302

PubMed ID: 9302301

SO-VID: ceba1f5a-6401-492e-b4a2-b05ace3dfb5e

History

Data availability:

Comments

Comment on this article

scite_

0

Smart Citations

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.